ClinicalTrials.gg
Active, not recruitingNCT03833700Updated Feb 27, 2026

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

A Phase 1 interventional study of E7386 in Solid Neoplasms, Colorectal Neoplasms and Gastrointestinal Tumors, sponsored by Eisai Co., Ltd.. Active, not recruiting at 8 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Colorectal Neoplasms by Eisai Co., Ltd. — none open to participants now, 2 under way, none of them phase 3. Colorectal Neoplasms · Eisai Co., Ltd..

Planned enrollment
4th of 10
70 · median 44
Started
2019
with 1 other
Phase 1
3 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Colorectal Neoplasms by Eisai Co., Ltd., this one is the 4th largest by planned enrollment, is one of 2 that started in 2019, is one of 3 in phase 1, and was the 7th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

None of the 10 studies in Colorectal Neoplasms by Eisai Co., Ltd. is open now. The open studies under Colorectal Neoplasms, anywhere →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Colorectal Neoplasms by Eisai Co., Ltd. as a file.
02

Study summary

This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.

Read the detailed description

The study will be conducted in 3 parts: dose escalation part, expansion part 1 and expansion part 2. The study will consist of Primary Assessment Phase and Continuation Phase. Primary Assessment Phase will include Pre-treatment Phase, Treatment Phase and Extension Phase (in expansion parts only).

After Treatment Phase, participants will be followed in follow-up period of Extension Phase (in expansion parts only). All participants who are still on study drug at the time of data cutoff date for the planned primary analysis will enter the Continuation phase and continue to receive E7386.

03

Conditions studied

  • Solid Neoplasms
  • Colorectal Neoplasms
  • Gastrointestinal Tumors

Keywords

  • Solid Tumor
  • Colorectal Cancer
  • E7386
  • Small Bowel Carcinoma
  • Gastrointestinal Neuroendocrine Tumor
  • Adrenocortical carcinoma
  • Desmoid Tumor
  • Solid pseudopapillary neoplasm of pancreas
  • Hepatocellular carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with a histological and/or cytological diagnosis of solid tumor must have any of the following tumor types:

    1. Dose Escalation Part: Participants with advanced, unresectable, or recurrent solid tumor including CRC for which no alternative standard therapy or no effective therapy exists
    2. Expansion Part 1: Participants with advanced, unresectable, or recurrent CRC in third- or , Or participants with other gastrointestinal tumors such as small bowel carcinoma and gastrointestinal neuroendocrine tumors after at least 1 prior systemic chemotherapy regimen upon discussion and agreement with the sponsor
    3. Expansion Part 2: Participants with advanced, unresectable, or recurrent solid tumors expected to be highly dependent on wingless/integrated (Wnt)/β-catenin signaling pathway as specified below, who have no standard therapy. Disease progression must be confirmed within the past 12 months.

      • Desmoid tumor
      • Solid pseudopapillary neoplasm (SPN) of pancreas
      • Small bowel carcinoma with mutation of catenin beta-1 (CTNNB1) or adenomatous polyposis coli (APC)
      • Adrenocortical carcinoma (ACC) with mutation of CTNNB1, APC or zinc and ring finger 3 (ZNRF3)
      • Solid tumors (except for CRC) with APC mutation in participants diagnosed as familial adenomatous polyposis (FAP)
      • Hepatocellular carcinoma (HCC) with CTNNB1 gain-of-function mutation
      • Other types of solid tumors (except for CRC) harboring one or more Wnt-related gene mutations (example, APC, AXIN1, CTNNB1, ring finger protein 43 [RNF43], et cetera) expected to be highly dependent on Wnt/β-catenin signaling pathway based on emerging data may be enrolled upon consultation and agreement with the sponsor.

    HCC participants must have:

    1. A diagnosis of HCC that is or cytologically confirmed (excluding fibrolamellar, sarcomatoid or mixed cholangio-HCC tumors) or clinically confirmed according to American Association for the Study of Liver Disease criteria, including cirrhosis of any etiology and/or chronic or C infection.
    2. Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy or to locoregional therapy, and not amenable to a curative treatment approach
  2. of >=12 weeks.
  3. (ECOG) Performance Status of 0-1.
  4. All AEs due to previous anti-cancer therapy have either returned to Grade 0-1 except for alopecia and Grade 2 peripheral neuropathy (renal/bone marrow/liver function should meet the inclusion criteria).
  5. Adequate before study drug administration:

    1. Chemotherapy and radiotherapy: 3 weeks or more
    2. Any therapy with antibody (Ab): 4 weeks or more
    3. Any drug or device: 4 weeks or more
    4. Blood/ transfusion or Granulocyte-colony stimulating factor (G-CSF): 2 weeks or more
  6. Adequate renal, bone marrow, liver function, and serum mineral level.
  7. At least one based on 1.1.
  8. Dose escalation part: Participants must consent to skin from skin tissue that is tumor-free during the study. Expansion part 1: At least 5 participants in each dose level must consent to skin biopsies from skin tissue that is tumor-free during the study. Participants may be enrolled without skin biopsies upon consultation and agreement by the sponsor. Expansion part 2: Participants must consent to skin biopsies from skin tissue that is tumor-free during the study in principle. Participants may be enrolled without consent to skin biopsies upon consultation and agreement by the sponsor.

Exclusion criteria

Exclusion Criteria:

  1. Known to be (HIV) positive.
  2. Active infection requiring systemic treatment.

    For participants with HCC in Expansion part 2: In case of surface antigen (HBsA g) positive (+) participants:

    1. Antiviral therapy for Hepatitis B virus (HBV) is not ongoing
    2. HBV viral load is 2000 International units per milliliter (IU/mL) or more at the Screening Period although antiviral therapy for HBV is ongoing
    3. Has dual active HBV infection (HBsAg [+] and/or detectable HBV Deoxyribonucleic acid [DNA]) and virus (HCV) infection (anti-HCV Ab [+] and detectable HCV Ribonucleic acid [RNA]) at study entry
  3. Diagnosed with meningeal carcinomatosis.
  4. Participants with brain or subdural are not eligible, unless they have completed local therapy and have discontinued the use of for this indication for at least 4 weeks before starting treatment in this study. Any signs (example: radiologic) or symptoms of must be stable for at least 4 weeks before starting study treatment.
  5. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.
  6. Any of bone disease/conditions as follows;

    1. Osteoporosis with T-score less than (\<) -3 at the left or right total hip, left or right femoral neck or lumbar spine (L1-L4) as determined by dual energy X-ray absorptiometry (DXA) scan. Participants with T-score \<-2.5 to -3.0 and no prior medical therapy for osteoporosis can only be included provided that treatment with a bisphosphonate (example, zoledronic acid) or denosumab has been started at least 14 days prior to the first dose of study drug
    2. Metabolic bone disease, such as hyperparathyroidism, Paget's disease or osteomalacia
    3. Symptomatic hypercalcemia requiring bisphosphonate therapy
    4. History of any fracture within 6 months prior to starting study drug
    5. Any condition requiring orthopedic intervention
    6. Bone metastasis, not being treated by bisphosphonate or denosumab. Participant may be included if treatment with bisphosphonate or denosumab have been started at least 14 days prior to the first dose of study drug. Participants with previous solitary bone lesions controlled with radiotherapy are eligible
    7. History of symptomatic vertebral fragility fracture or any fragility fracture of the hip, pelvis, wrist or other location (defined as any fracture without a history of trauma or because of a fall from standing height or less)
    8. Moderate (25 percent [%] to 40% decrease in the height of any vertebrae) or severe (more than [>] 40% decrease in the height of any vertebrae) morphometric vertebral fracture at baseline.
  7. History of active (except for original disease, or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, carcinoma in-situ of the bladder or cervix, or early stage gastric/colorectal cancer) within the past 24 months prior to the first dose of study drug.
  8. For participants with HCC in Expansion part 2, if the participants have:

    1. status of B and C
    2. History of hepatic encephalopathy within 6 months prior to starting study drug unresponsive to therapy within 3 days. Participants on rifaximin or lactulose during screening to control their hepatic encephalopathy are not allowed
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Part: E7386

    Participants will receive E7386 in 28-days treatment cycle until disease progression (PD), development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program.

    Drug: E7386

  • Experimental
    Expansion Part 1

    Participants will receive E7386 in 28-days treatment cycle until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program.

    Drug: E7386

  • Experimental
    Expansion Part 2

    Participants will receive E7386 in 28-days treatment cycle until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program.

    Drug: E7386

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose-limiting Toxicities (DLTs)

    DLT will be defined as any of the events that are considered by the investigator to be at least possibly related to therapy with the study medication. Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0).

    Time frame: Baseline up to Cycle 1 (Cycle length is equal to [=] 28 days)

  2. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 30 days after the last dose of study drug or before initiating post anti-cancer treatment (approximately 6 years)

Secondary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for E7386

    Time frame: Dose escalation Part, Cycles 1 to 6: Up to Day 8; Dose Expansion Part 1 and 2, Cycles 1 and 2: Up to Day 8 (Cycle length=28 days)

  2. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7386

    Time frame: Dose escalation Part, Cycles 1 to 6: Up to Day 8; Dose Expansion Part 1 and 2, Cycles 1 and 2: Up to Day 8 (Cycle length=28 days)

  3. AUC: Area Under the Plasma Concentration Versus Time Curve for E7386

    Time frame: Dose escalation Part, Cycles 1 to 6: Up to Day 8; Dose Expansion Part 1 and 2, Cycles 1 and 2: Up to Day 8 (Cycle length=28 days)

  4. CL/F: Apparent Total Body Clearance for E7386

    Time frame: Dose escalation Part, Cycles 1 to 6: Up to Day 8; Dose Expansion Part 1 and 2, Cycles 1 and 2: Up to Day 8 (Cycle length=28 days)

  5. Vz/F: Apparent Volume of Distribution for E7386

    Time frame: Dose escalation Part, Cycles 1 to 6: Up to Day 8; Dose Expansion Part 1 and 2, Cycles 1 and 2: Up to Day 8 (Cycle length=28 days)

  6. Objective Response Rate (ORR)

    The ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). The ORR will be assessed by investigator based on RECIST version 1.1.

    Time frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 6 years)

  7. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with a BOR of CR, PR, or stable disease (SD). The DCR will be assessed by investigator based on RECIST version 1.1.

    Time frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 6 years)

  8. Clinical Benefit Rate (CBR)

    The CBR is defined as the percentage of participants with a BOR of CR, PR, or durable SD. The CBR will be assessed by investigator based on RECIST version 1.1.

    Time frame: From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 6 years)

  9. Progression-free Survival (PFS)

    PFS is defined as the time from the date of the first dose to the date of the first documentation of confirmed PD or death, whichever occurs first.

    Time frame: From first dose of study drug until PD, or death from any cause, whichever occurs first (up to approximately 6 years)

  10. Duration of Response (DOR)

    DOR is defined as the time from the first date of documented CR or PR to the date of PD or death, whichever occurs first. It will be calculated for participants whose BOR is CR or PR. DOR will be assessed according to RECIST version 1.1.

    Time frame: From the date of first documented CR or PR until first documentation of PD or death (up to approximately 6 years)

  11. Overall Survival (OS)

    OS is defined as the time from the date of first dose to the date of death.

    Time frame: From first dose of study drug until date of death (up to approximately 6 years)

07

Study locations

8 sites
  • Eisai Trial Site#7
    Nagoya, Aichi-ken, Japan
  • Eisai Trial Site #2
    Kashiwa, Chiba, Japan
  • Eisai Trial Site #5
    Sapporo, Hokkaido, Japan
  • Eisai Trial Site#8
    Sendai, Miyagi, Japan
  • Eisai Trial Site #3
    Nagaizumi-cho, Shizuoka, Japan
  • Eisai Trial Site #1
    Chuo Ku, Tokyo, Japan
  • Eisai Trial Site #4
    Fukuoka, Japan
  • Eisai Trial Site#6
    Osaka, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Mar 2027, 96 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 96 months is above that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2019
First posted
Feb 7, 2019
StartActual
Mar 5, 2019
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03833700
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Feb 7, 2019
Start date
Mar 5, 2019
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Feb 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: E-7386

Start the discussion